Schizophrenia Research
Volume 76, Issue 2 , Pages 173-185 , 15 July 2005

N-acetylaspartate reductions in the mediodorsal and anterior thalamus in men with schizophrenia verified by tissue volume corrected proton MRSI

  • Angela Jakary

      Affiliations

    • Psychiatry Service, 116-N, Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
    • ,
  • Sophia Vinogradov

      Affiliations

    • Psychiatry Service, 116-N, Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
    • Department of Psychiatry, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA, USA
    • ,
  • Robert Feiwell

      Affiliations

    • Department of Radiology, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA, USA
    • ,
  • Raymond F. Deicken

      Affiliations

    • Psychiatry Service, 116-N, Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
    • Department of Psychiatry, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA, USA
    • Corresponding Author InformationCorresponding author. Psychiatry Service, 116-N, Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA. Tel.: +1 415 221 4810x4350; fax: +1 415 750 6648.

Received 20 October 2004 ,Revised 17 February 2005 ,Accepted 21 February 2005.

References 

  1. Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Leonard Watkins G, Boles Ponto LL, et al. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet. 1997;349:1730–1734
  2. Arciniegas D, Rojas DC, Teale P, Sheeder J, Sandberg E, Reite M. The thalamus and the schizophrenia phenotype: failure to replicate reduced volume. Biol. Psychiatry. 1999;45:1329–1335
  3. Arnold DL, de Stefano N, Matthews PM, Trapp BD. N-acetylaspartate: usefulness as an indicator of viable neuronal tissue. Ann. Neurol. 2001;50:823–825
  4. Auer DP, Wilke M, Grabner A, Heidenreich JO, Bronisch T, Wetter TC. Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. Schizophr. Res. 2001;52:87–99
  5. Barker PB. N-acetylaspartate—a neuronal marker?. Ann. Neurol. 2001;49:423–424
  6. Baslow MH. Evidence supporting a role for N-acetyl-l-aspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review. Neurochem. Int. 2002;40:295–300
  7. Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CT, et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry. 1996;153:1554–1563
  8. Bertolino A, Callicott JH, Elman I, Mattay VS, Tedeschi G, Frank JA, et al. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol. Psychiatry. 1998;43:641–648
  9. Bertolino A, Breier A, Callicott JH, Adler C, Mattay VS, Shapiro M, et al. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology. 2000;22:125–132
  10. Bertolino A, Sciota D, Brudaglio F, Altamura M, Blasi G, Bellomo A, et al. Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am. J. Psychiatry. 2003;160:483–489
  11. Bhakoo KK, Pearce D. In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J. Neurochem. 2000;74:254–262
  12. Bjartmar C, Battistuta J, Terada N, Dupree E, Trapp BD. N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann. Neurol. 2002;51:51–58
  13. Blennow K, Bogdanovic N, Heilig M, Grenfeldt B, Karlsson I, Davidsson P. Reduction of the synaptic protein rab3a in the thalamus and connecting brain regions in post-mortem schizophrenic brains. J. Neural Transm. 2000;107:1085–1097
  14. Braus DF, Weber-Fahr W, Tost H, Ruf M, Henn FA. Sensory information processing in neuroleptic-naive first-episode schizophrenic patients: a functional magnetic resonance imaging study. Arch. Gen. Psychiatry. 2002;59:696–701
  15. Bridle N, Pantelis C, Wood SJ, Coppola R, Velakoulis D, McStephen M, et al. Thalamic and caudate volumes in monozygotic twins discordant for schizophrenia. Aust. N. Z. J. Psychiatry. 2002;36:347–354
  16. Buchsbaum MS, Someya T, Teng CY, Abel L, Chin S, Najafi A, et al. PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am. J. Psychiatry. 1996;153:191–199
  17. Bustillo JR, Lauriello J, Rowland LM, Jung RE, Petropoulos H, Hart BL, et al. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Res. Neuroimaging. 2001;107:135–149
  18. Bustillo JR, Lauriello J, Rowland LM, Thomson LM, Petropoulos H, Hammond R, et al. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr. Res. 2002;58:313–321
  19. Byne W, Buchsbaum MS, Kemether E, Hazlett EA, Shinwari A, Mitropoulou V, et al. Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder. Arch. Gen. Psychiatry. 2001;58:133–140
  20. Byne W, Buchsbaum MS, Mattiace LA, Hazlett EA, Kemether E, Elhakem SL, et al. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am. J. Psychiatry. 2002;159:59–65
  21. Cardenas VA, Ezekiel F, Di Sclafani V, Gomberg B, Fein G. Reliability of tissue volumes and their spatial distribution for segmented magnetic resonance images. Psychiatry Res. 2001;106:193–205
  22. Chakraborty G, Mekala P, Yahya D, Wu G, Ledeen RW. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J. Neurochem. 2001;78:736–745
  23. Clark JB. N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev. Neurosci. 1998;20:271–276
  24. Cochran SM, McKerchar CE, Morris BJ, Pratt JA. Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol. Neuropharmacology. 2002;43:394–407
  25. Cohen BM, Wan W, Froimowitz MP, Ennulat DJ, Cherkerzian S, Honieczna H. Activation of midline thalamic nuclei by antipsychotic drugs. Psychopharmacology. 1998;135:37–43
  26. Collins DL, Zijdenbos AP, Kollokian V, Sled JG, Kabani NJ, Holmes CJ, et al. Design and construction of a realistic digital brain phantom. IEEE Trans. Med. Imag. 1998;17:463–468
  27. Crespo-Facorro B, Paradiso S, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, et al. Recalling word lists reveals “cognitive dysmetria” in schizophrenia: a positron emission tomography study. Am. J. Psychiatry. 1999;156:386–392
  28. Cullen TJ, Walker MA, Parkinson N, Craven R, Crow TJ, Esiri MM, et al. A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia. Schizophr. Res. 2003;60:157–166
  29. Danos P, Baumann B, Kramer A, Bernstein HG, Stauch R, Krell D, et al. Volumes of association thalamic nuclei in schizophrenia: a postmortem study. Schizophr. Res. 2003;60:141–155
  30. Deicken RF, Johnson C, Eliaz Y, Schuff N. Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia. Am. J. Psychiatry. 2000;157:644–647
  31. Deicken RF, Eliaz Y, Feiwell R, Schuff N. Increased thalamic N-acetylaspartate in male patients with familial bipolar I disorder. Psychiatry Res. Neuroimaging. 2001;106:35–45
  32. Delamillieure P, Constans JM, Fernandez J, Brazo P, Dollfus S. Proton magnetic resonance spectroscopy (1H-MRS) of the thalamus in schizophrenia. Eur. Psychiatr. 2000;15:489–491
  33. Ende G, Braus DF, Walter S, Henn FA. Lower concentration of thalamic N-acetylaspartate in patients with schizophrenia: a replication study. Am. J. Psychiatry. 2001;158:1314–1316
  34. Ettinger U, Chitnis XA, Kumari V, Fannon DG, Sumich AL, O'Ceallaigh S, et al. Magnetic resonance imaging of the thalamus in first-episode psychosis. Am. J. Psychiatry. 2001;158:116–118
  35. Gilbert AR, Rosenberg DR, Harenski K, Spencer S, Sweeney JA, Keshavan MS. Thalamic volumes in patients with first-episode schizophrenia. Am. J. Psychiatry. 2001;158:618–624
  36. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry. 2001;158:1367–1377
  37. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am. J. Psychiatry. 1998;155:1711–1717
  38. Hagino H, Suzuki M, Mori K, Nohara S, Yamashita I, Takahashi T, et al. Proton magnetic resonance spectroscopy of the inferior frontal gyrus and thalamus and its relationship to verbal learning task performance in patients with schizophrenia: a preliminary report. Psychiatry Clin. Neurosci. 2002;56:499–507
  39. Hazlett EA, Buchsbaum MS, Byne W, Wei TC, Spiegel-Cohen J, Geneve C, et al. Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am. J. Psychiatry. 1999;156:1190–1199
  40. Hazlett EA, Buchsbaum MS, Kemether E, Bloom R, Platholi J, Brickman AM, et al. Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia. Am. J. Psychiatry. 2004;161:305–314
  41. Heimberg C, Komoroski RA, Lawson WB, Cardwell D, Karson CN. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiatry Res. 1998;83:105–115
  42. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am. J. Psychiatry. 1996;153:41–49
  43. Ibrahim HM, Hogg AJ, Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am. J. Psychiatry. 2000;157:1811–1823
  44. Jayasundar R. Human brain: biochemical lateralization in normal subjects. Neurol. India. 2002;50:267–271
  45. Katz M, Buchsbaum MS, Siegel BV, Wu J, Haier RJ, Bunney WE. Correlational patterns of cerebral glucose metabolism in never-medicated schizophrenics. Neuropsychobiology. 1996;33:1–11
  46. Kawachi T, Ishii K, Sakamoto S, Matsui M, Mori T, Sasaki M. Gender differences in cerebral glucose metabolism: a PET study. J. Neurol. Sci. 2002;199:79–83
  47. Keshavan MS, Stanley JA, Pettegrew JW. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings—part II. Biol. Psychiatry. 2000;48:369–380
  48. Kwan RK, Evans AC, Pike GB. MRI simulation-based evaluation of image-processing and classification methods. IEEE Trans. Med. Imag. 1999;18:1085–1097
  49. Lim KO, Adalsteinsson E, Spielman D, Sullivan EV, Rosenbloom MJ, Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch. Gen. Psychiatry. 1998;55:346–352
  50. Magnotta VA, Gold S, Andreasen NC, Ehrhardt JC, Yuh WTC. Visualization of subthalamic nuclei with cortex attenuated inversion recovery MR imaging. NeuroImage. 2000;11:341–346
  51. Martin E, Capone A, Schneider J, Hennig J, Thiel T. Absence of N-acetylaspartate in the human brain: impact on neurospectroscopy?. Ann. Neurol. 2001;49:518–521
  52. Maudsley AA, Lin E, Weiner MW. Spectroscopic imaging display and analysis. Magn. Reson. Imaging. 1992;10:471–485
  53. McCarley RW, Wible CG, Frumin M, Hirayasu Y, Levitt JJ, Fischer IA, et al. MRI anatomy of schizophrenia. Biol. Psychiatry. 1999;45:1099–1119
  54. Nagae-Poetscher LM, Bonekamp D, Barker PB, Brant LJ, Kaufmann WE, Horska A. Asymmetry and gender effect in functionally lateralized cortical regions: a proton MRS imaging study. J. Magn. Reson. Imaging. 2004;19:27–33
  55. Noworolski SM, Nelson SJ, Henry RG, Day MR, Wald LL, Star-Lack J, et al. High spatial resolution 1H-MRSI and segmented MRI of cortical gray matter and subcortical white matter in three regions of the human brain. Magn. Reson. Med. 1999;41:21–29
  56. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 1999;33:523–533
  57. Omori M, Murata T, Kimura H, Koshimoto Y, Kado H, Ishimori Y, et al. Thalamic abnormalities in patients with schizophrenia revealed by proton magnetic resonance spectroscopy. Psychiatry Res. Neuroimaging. 2000;98:155–162
  58. O'Neill J, Eberling JL, Schuff N, Jagust W, Reed B, Soto G, et al. Method to correlate 1H MRSI and 18FDG-PET. Magn. Reson. Med. 2000;43:244–250
  59. O'Neill J, Levitt J, Caplan R, Asarnow R, McCracken JT, Toga AW, et al. 1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia. NeuroImage. 2004;21:1781–1789
  60. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch. Gen. Psychiatry. 1990;47:1023–1028
  61. Pakkenberg B. The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics. Schizophr. Res. 1992;7:95–100
  62. Petroff OA, Errante LD, Rothman DL, Kim JH, Spencer DD. Neuronal and glial metabolite content of the epileptogenic human hippocampus. Ann. Neurol. 2002;52:635–642
  63. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn. Reson. Med. 1999;41:276–284
  64. Popken GJ, Bunney WE, Potkin SG, Jones EG. Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. PNAS. 2000;97:9276–9280
  65. Portas CM, Goldstein JM, Shenton ME, Hokama HH, Wible CG, Fischer I, et al. Volumetric evaluation of the thalamus in schizophrenic male patients using magnetic resonance imaging. Biol. Psychiatry. 1998;43:649–659
  66. Rubia K, Russell T, Bullmore ET, Soni W, Brammer MJ, Simmons A, et al. An fMRI study of reduced left prefrontal activation in schizophrenia during normal inhibitory function. Schizophr. Res. 2001;52:47–55
  67. Salgado-Pineda P, Baeza I, Perez-Gomez M, Vendrell P, Junque C, Bargallo N, et al. Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naive schizophrenic patients. NeuroImage. 2003;19:365–375
  68. Schlosser R, Gesierich T, Kaufmann B, Vucurevic G, Hunsche S, Gawehn J, et al. Altered effective connectivity during working memory performance in schizophrenia: a study with fMRI and structural equation modeling. NeuroImage. 2003;19:751–763
  69. Soher BJ, Young K, Govindaraju V, Maudsley A. Automated spectral analysis III: applications to in vivo proton MR spectroscopy and spectroscopic imaging. Magn. Reson. Med. 1998;40:822–831
  70. Sowell ER, Toga AW, Asarnow R. Brain abnormalities observed in childhood-onset schizophrenia: a review of the structural magnetic resonance imaging literature. Ment. Retard. Dev. Disabil. Res. Rev. 2000;6:180–185
  71. Spinks R, Magnotta VA, Andreasen NC, Albright KC, Ziebell S, Nopoulos P, et al. Manual and automated measurement of the whole thalamus and mediodorsal nucleus using magnetic resonance imaging. NeuroImage. 2002;17:631–642
  72. Staal WG, Hulshoff Pol HE, Schnack H, van der Schot AC, Kahn RS. Partial volume decrease of the thalamus in relatives of patients with schizophrenia. Am. J. Psychiatry. 1998;155:1784–1786
  73. Staal WG, Hulshoff Pol HE, Schnack HG, van Haren NEM, Seifert N, Kahn RS. Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum. Am. J. Psychiatry. 2001;158:1140–1142
  74. Steen RG, Reddick WE, Ogg RJ. More than meets the eye: significant regional heterogeneity in human cortical T1. Magn. Reson. Imaging. 2000;18:361–368
  75. Stephan KE, Magnotta VA, White T, Arndt S, Flaum M, O'Leary DS, et al. Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task. Psychol. Med. 2001;31:1065–1078
  76. Sullivan EV, Rosenbloom MJ, Serventi KL, Deshmukh A, Pfefferbaum A. Effects of alcohol dependence comorbidity and antipsychotic medication on volumes of the thalamus and pons in schizophrenia. Am. J. Psychiatry. 2003;160:1110–1116
  77. Supprian T, Hofmann E, Warmuth-Metz M, Franzek E, Becker T. MRI T2 relaxation times of brain regions in schizophrenic patients and control subjects. Psychiatry Res. 1997;75:173–182
  78. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry. 2002;159:1944–1946
  79. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am. J. Psychiatry. 2003;160:2231–2233
  80. Tsai G, Coyle J. N-acetylaspartate in neuropsychiatric disorders. Prog. Neurobiol. 1995;46:531–540
  81. Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J. Neurochem. 1992;59:55–61
  82. Volz HP, Gaser C, Sauer H. Supporting evidence for the model of cognitive dysmetria in schizophrenia—a structural magnetic resonance imaging study using deformation-based morphometry. Schizophr. Res. 2000;46:45–56
  83. Wang Y, Li S. Differentiation of metabolic concentrations between gray matter and white matter of human brain by in vivo 1H magnetic resonance spectroscopy. Magn. Reson. Med. 1998;39:28–33
  84. Weber-Fahr W, Ende G, Braus DF, Bachert P, Soher BJ, Henn FA, et al. A fully automated method for tissue segmentation and CSF-correction of proton MRSI metabolites corroborates abnormal hippocampal NAA in schizophrenia. NeuroImage. 2002;16:49–60
  85. Wiegell MR, Tuch DS, Larsson HB, Wedeen VJ. Automatic segmentation of thalamic nuclei from diffusion tensor magnetic resonance imaging. NeuroImage. 2003;19:391–401
  86. Willis MW, Ketter TA, Kimbrell TA, George MS, Herscovitch P, Danielson AL, et al. Age, sex and laterality effects on cerebral glucose metabolism in healthy adults. Psychiatry Res. 2002;114:23–37
  87. Young KA, Manaye KF, Liang C, Hicks PB, German DC. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol. Psychiatry. 2000;47:944–953

PII: S0920-9964(05)00077-0

doi: 10.1016/j.schres.2005.02.012

Schizophrenia Research
Volume 76, Issue 2 , Pages 173-185 , 15 July 2005

Article Tools

* Image Usage & Resolution